BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18369635)

  • 1. Substratification of high-risk localised prostate cancer treated by radical prostatectomy.
    Lodde M; Harel F; Lacombe L; Fradet Y
    World J Urol; 2008 Jun; 26(3):225-9. PubMed ID: 18369635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
    Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy.
    Mossanen M; Nepple KG; Grubb RL; Androile GL; Kallogjeri D; Klein EA; Stephenson AJ; Kibel AS
    Eur Urol Oncol; 2018 Jun; 1(2):143-148. PubMed ID: 31100238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.
    Ploussard G; Masson-Lecomte A; Beauval JB; Ouzzane A; Bonniol R; Buge F; Fadli S; Rouprêt M; Rebillard X; Gaschignard N; Pfister C; Villers A; Soulié M; Salomon L;
    Urology; 2011 Sep; 78(3):607-13. PubMed ID: 21783233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between pre-operative PSA and prostate cancer-specific mortality in patients with long-term follow-up after radical prostatectomy.
    Lewinshtein D; Teng B; Valencia A; Gibbons R; Porter CR
    Prostate; 2012 Jan; 72(1):24-9. PubMed ID: 21520159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
    Stokes SH
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
    Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
    Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score D'Amico AV; Wu Y; Chen MH; Nash M; Renshaw AA; Richie JP
    Cancer; 2000 Oct; 89(8):1810-7. PubMed ID: 11042577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?
    Klaassen Z; Singh AA; Howard LE; Feng Z; Trock B; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Partin A; Han M; Freedland SJ
    Cancer; 2015 May; 121(9):1414-21. PubMed ID: 25492369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of radical prostatectomy for prostate cancer from a single institution].
    Ishida R; Kobayashi H; Yoshida S; Ogawa M; Shiota T; Nishikimi T; Yamada H; Yokoi K
    Nihon Hinyokika Gakkai Zasshi; 2009 Sep; 100(6):615-24. PubMed ID: 19827538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy.
    Pierorazio PM; Lin BM; Mullins JK; Hyndman ME; Schaeffer EM; Han M; Partin AW; Pavlovich CP
    Urol Oncol; 2013 Jul; 31(5):589-94. PubMed ID: 21664838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
    van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
    Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.